Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis
1. 系统已在2026-09-10 15:34:12对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
K Liu, J Choi, A Le, TCF Yip, VWS Wong…
Alimentary …, 2019
Wiley Online Library
Background Lamivudine and entecavir reduce hepatic events and death in chronic hepatitis B (CHB) patients with cirrhosis, but the impact of tenofovir disoproxil fumarate (TDF) is less well studied. Aim To investigate the effectiveness of TDF therapy in CHB patients with cirrhosis. Methods We studied TDF‐treated and untreated CHB patients with cirrhosis from three tertiary centres. TDF cohort included consecutive patients who received TDF for≥ 12 months while the untreated cohort were historical controls receiving routine clinical care …
